Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
DPP-IVi, Other

Diamyd Initiates Ph2 Trial in At-risk Individuals; Teladoc Cuts 300 Jobs; Merck to Resolve Sitagliptin Contamination Issue

Here is a brief preview of this blast: Three cardiometabolic-related news items have been observed: Diamyd initiated a new Ph2 trial evaluating its vaccine in individuals at risk for T1DM (DiaPrecise; view CT.gov record); Teladoc disclosed it is laying off 300 employees which represent 6% of its workforce (view Form 8-K); and Merck has determined the source of the sitagliptin NTTP contamination issue (view article). Below, FENIX provides highlights and insights for the respective news items, including thoughts on Diamyd’s development plan in the context of the ongoing Tzield launch.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.